<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="64522">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02265952</url>
  </required_header>
  <id_info>
    <org_study_id>R1500-CL-1331</org_study_id>
    <nct_id>NCT02265952</nct_id>
  </id_info>
  <brief_title>Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)</brief_title>
  <official_title>An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm study to assess the reduction of low-density lipoprotein
      cholesterol (LDL-C) by REGN1500 in patients with homozygous familial hypercholesterolemia
      (HoFH).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in low-density lipoprotein cholesterol (LDL-C) from baseline (week 0) to week 4.</measure>
    <time_frame>Week 0 to week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in LDL-C from week 2 to week 4</measure>
    <time_frame>Week 2 to week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in LDL-C from week 2 to week 4</measure>
    <time_frame>Week 2 to week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in LDL-C over time in the main study period</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in LDL-C over time in the main study period</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in LDL-C from baseline over time in the open label extension (OLE) period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in LDL-C from baseline over time in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in LDL-C from baseline (week 0) to week 4</measure>
    <time_frame>Week 0 to week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Apo B, non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (total-C), and lipoprotein (Lp) (a) over time in the main study period</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in Apo B, non-HDL-C, total-C, and Lp (a) over time in the main study period</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Apo B, non-HDL-C, total-C, and Lp (a) from baseline over time in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Apo B, non-HDL-C, total-C, and Lp (a) from baseline over time in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieve a reduction in LDL-C of ≥15% from baseline in the main study</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieve a reduction in LDL-C of ≥15% from baseline in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ≥30% reduction in LDL-C from baseline in the main study</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ≥30% reduction in LDL-C from baseline in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in HDL-C, triglycerides, and Apo A-1 over time in the main study period</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in HDL-C, triglycerides, and Apo A-1 over time in the main study period</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in HDL-C, triglycerides, and Apo A-1 from baseline over time in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in HDL-C, triglycerides, and Apo A-1 from baseline over time in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Apo CIII over time in the main study period</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in Apo CIII over time in the main study period</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Apo CIII from baseline over time in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Apo CIII from baseline over time in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events (TEAEs) reported from the first dose of study drug to the end of study or the last visit in subjects treated with REGN1500</measure>
    <time_frame>Week 2 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of REGN1500 over time</measure>
    <time_frame>Week 0 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and titer of anti-REGN1500 antibodies over time</measure>
    <time_frame>Week 0 to week 214</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Open-Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label REGN1500</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN1500</intervention_name>
    <arm_group_label>Open-Label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women ≥18 years of age at the time of the screening visit

          2. Diagnosis of homozygous familial hypercholesterolemia (HoFH)

          3. Willing to consistently maintain usual diet for the duration of the study

        Exclusion Criteria:

          1. Background medical lipid modifying therapy that has not been stable for at least 4
             weeks (6 weeks for fibrates) prior to the screening visit

          2. Having undergone lipid apheresis within 4 weeks prior to the screening visit

          3. Use of another investigational drug or therapy within 30 days or at least 5
             half-lives (whichever is longer) prior to the screening visit

          4. Previous participation in any clinical trial of REGN1500

        Note: The information listed above is not intended to contain all considerations relevant
        to a patient's potential participation in this clinical trial therefore not all inclusion/
        exclusion criteria are listed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 26, 2017</lastchanged_date>
  <firstreceived_date>October 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
